Precision Bio climbs on near-$1.5bn sickle cell pact with Novartis
pharmaphorum
JUNE 23, 2022
The deal comes a year after Intellia and partner Regeneron reported promising results from the first clinical trial of a drug used to edit the genomes of cells within the body, in patients with rare disease ATTR amyloidosis. billion in potential milestones if the project advances through development and onto the market.
Let's personalize your content